CN107298698B - 一种非同源末端体系、制备方法及应用 - Google Patents

一种非同源末端体系、制备方法及应用 Download PDF

Info

Publication number
CN107298698B
CN107298698B CN201710414508.XA CN201710414508A CN107298698B CN 107298698 B CN107298698 B CN 107298698B CN 201710414508 A CN201710414508 A CN 201710414508A CN 107298698 B CN107298698 B CN 107298698B
Authority
CN
China
Prior art keywords
leu
glu
ala
val
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201710414508.XA
Other languages
English (en)
Other versions
CN107298698A (zh
Inventor
周盈
张晓莉
王绪德
周亚凤
毕利军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foshan University
Original Assignee
Foshan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foshan University filed Critical Foshan University
Priority to CN201710414508.XA priority Critical patent/CN107298698B/zh
Publication of CN107298698A publication Critical patent/CN107298698A/zh
Application granted granted Critical
Publication of CN107298698B publication Critical patent/CN107298698B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了一种非同源末端体系、制备方法及应用。所述非同源末端体系包括Ku K19R蛋白和LigD蛋白。所述的具有Ku K19R蛋白的非同源末端体系在连接双链DNA片段时,比传统的非同源末端体系具有更高的产物数量,即具有更佳的连接效果。

Description

一种非同源末端体系、制备方法及应用
技术领域
本发明涉及分子工程技术领域,特别涉及一种非同源末端体系、制备方法及应用。
背景技术
双链DNA片段的连接是分子生物学实验中的一个关键技术,该技术是基因重组和基因改造的重要中间环节。一般利用DNA连接酶催化两个相邻双链DNA片段的5’端磷酸与3’端羟基之间形成磷酸二酯键。T4噬菌体DNA连接酶是科研的首选连接酶,例如Promega公司出品的M1801、NEB公司出品的M0202等。T4噬菌体DNA连接酶的作用分三步:(1)连接酶与辅助因子ATP形成酶-AMP复合物;(2)酶-AMP复合物结合到具有5’-磷酸基切口的DNA末端,形成DNA-AMP复合物;(3)DNA-AMP复合物的3’-羟基和5’-磷酸基产生新的磷酸二酯键,释放AMP。连接酶作用的两个双链DNA片段的末端必须具有5’-磷酸基、3’-羟基和末端碱基互补的特性,一般通过限制性内切酶产生。
同源重组也在分子生物学实验中被用来进行目的与载体DNA片段之间的双链DNA片段连接,也被称为无缝克隆技术,是利用重组酶将末端具有15-20个同源碱基的载体与目的DNA片段连在一起。与连接酶相比,利用重组酶连接DNA的步骤更简略,不需要限制性内切酶产生互补的DNA末端,但是重组酶发挥作用的前提是两个DNA末端之间有同源碱基。
同源重组和非同源末端(non-homologous endjoining,NHEJ)体系是生物体内的两套断裂DNA修复体系。同源重组发生在基因组复制时期,需要同时存在两个拷贝的基因组才能发挥作用,而非同源末端连接可以在任何时期发挥作用。与同源重组相比,非同源末端体系的作用底物更广泛。非同源末端体系存在于真核细胞和少数原核细胞中,能够连接任意两个双链DNA,对DNA末端碱基无特殊要求。最小NHEJ体系由Ku和LigD蛋白组成。Ku蛋白是DNA末端结合蛋白,能够结合具有不同结构特征的DNA末端,包括平末端、5’或者3’凸出和DNA发夹结构。Ku蛋白以同源二聚体的形式结合双链DNA末端,随后特异性招募LigD蛋白,并促进LigD蛋白进行双链DNA末端之间的连接反应。
发明内容
本发明的目的在于提供一种非同源末端体系,其通过改变Ku蛋白的氨基酸序列,从而达到更佳的连接效果。
本发明是通过以下技术方案实现的:
一种非同源末端体系,包括Ku K19R蛋白和LigD蛋白,所述KuK19R蛋白是如下a)或b)蛋白:
a)序列表中的SEQ ID №.1所示的氨基酸序列组成的蛋白质;
b)将序列表中的SEQ ID №.1的氨基酸残基序列经过一个或几个氨基酸残基的取代和/或缺失和/或添加且与SEQ ID №.1所示蛋白具有相同功能的由a)衍生的蛋白质;
所述LigD是如下c)或d)蛋白:
c)序列表中的SEQ ID №.2所示的氨基酸序列组成的蛋白质;
d)将序列表中的SEQ ID №.2的氨基酸残基序列经过一个或几个氨基酸残基的取代和/或缺失和/或添加且与SEQ ID №.2所示蛋白具有相同功能的由c)衍生的蛋白质。
本发明还提供了制备非同源末端体系的方法,包括构建Ku K19R蛋白表达菌株和纯化Ku K19R蛋白。
所述构建Ku K19R蛋白表达菌株包括以下步骤:
1-1)将Ku基因与载体连接;
1-2)利用定点突变引物A和B将Ku基因的第19位赖氨酸突变为精氨酸,获得KuK19R表达质粒;
1-3)将完成定点突变的Ku K19R表达质粒转入受体细胞。
所述纯化Ku K19R蛋白包括以下步骤:
2-1)将Ku K19R蛋白表达菌株划平板培养,挑取单克隆菌落于LB培养基中,在37℃、200rpm/min的条件下振荡培养过夜,次日按1%接种量转接于LB培养基中;
2-2)将转接的LB培养基在200rpm/min的条件下振荡培养至OD600值在0.4-0.6之间,添加IPTG诱导剂至终浓度0.4mM,30℃继续诱导培养4小时后,在4℃、8000rpm/min的条件下离心收集菌株沉淀,以缓冲液清洗菌体一次,然后重悬于缓冲液;
2-3)将重悬于缓冲液的菌株超声破碎后,以12000rpm/min离心30min,上清液上样于经缓冲液平衡的Ni2+-NTA亲和层析柱,然后用不同浓度imidazole依次洗脱。
本发明还提供了利用非同源末端体系连接双链DNA片段的方法:将待连接的双链DNA片段与上述非同源末端体系混合,在37℃条件下孵育1小时。
与现有技术相比,本发明所述的具有Ku K19R蛋白的非同源末端体系在连接双链DNA片段时,比传统的非同源末端体系具有更高的产物数量,即具有更佳的连接效果。
附图说明
图1是实施例3的PCR检测连接产物的结果图;
图2是实施例3的线性双链DNA连接两端的产物数量统计结果图。
具体实施方式
下面通过具体实施方式结合附图对本发明作进一步详细说明。但本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限定本发明的范围。实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。
实施例1:利用带有Ku K19R蛋白的非同源末端体系连接双链DNA片段
(一)Ku K19R和LigD蛋白的制备
1)构建Ku K19R和LigD蛋白表达菌株
从耻垢分枝杆菌(Mycobacterium smegmatis str.MC2 155)中,通过正向引物和反向引物,PCR扩增获得Ku基因编码片段和LigD基因编码片段,通过NEB公司货号分别为R3193、R3104和M0202酶将Ku基因编码片段连到pET28a载体(购自Novagen公司),货号分别为R3136、R3104和M0202酶将LigD基因编码片段连到pET28a载体。利用定点突变引物A和B(SEQ ID №.3和SEQ ID №.4)将Ku基因的第19位赖氨酸突变为精氨酸。质粒pET28a-KuK19R和pET28a-LigD分别转到大肠杆菌BL21中。
2)纯化Ku K19R蛋白和LigD蛋白
E.coli BL21/pET28a-LigD蛋白表达菌株和E.coliBL21/pET28a-Ku K19R蛋白表达菌株分别划平板,培养时添加抗生素的终浓度为卡拉霉素30μg/mL。挑取单克隆于5mL LB试管培养基,37℃200rpm/min振荡培养过夜。次日按1%接种量分别转接于500mL LB培养基中,200rpm/min振荡培养至OD600在0.4-0.6之间,加IPTG至终浓度0.4mM,30℃继续诱导培养4小时后,4℃,8000rpm/min离心收集细胞,细胞沉淀以缓冲液A(10mmol/L imidazole,0.5mol/L NaCl,20mmol/L Tris-HCl,pH 7.9)清洗菌体一次,然后重悬于50mL缓冲液A。超声破碎后,以12000rpm/min 30min离心,上清上样于经缓冲液A平衡的Ni2+-NTA亲和层析柱,然后用不同浓度imidazole(40mmol/L,80mmol/L和200mmol/L)依次洗脱。根据紫外检测仪的读数收集对应的洗脱物,SDS-PAGE电泳检验纯度后,用2L透析缓冲液B(20mmol/LTris-HCl,pH 7.9,NaCl150mmol/L,5%甘油)透析。透析好的蛋白样品用离心超滤杯浓缩后分成小份保存于-80℃。
(二)准备待连接的DNA片段
pET-20b(购自Novagen公司,货号69739)质粒经EcoR V(购自NEB公司,货号R3195)酶切产生4kB双链片段,琼脂糖凝胶电泳分离,切胶回收准备待连接的DNA片段。
(三)片段连接
10μl反应体系包含LigD蛋白1μg,Ku K19R蛋白分别选取10ng、40ng、200ng,50μMdNTPs,50mM pH为7.5的Tris-HCl,10mM MgCl2,1mM ATP,10mM Dithiothreitol和80ng待连接的DNA片段。混匀后,37℃条件下孵育1h。
实施例2:传统非同源末端体系连接双链DNA片段
10μl反应体系包含LigD蛋白1μg,Ku蛋白分别选取10ng、40ng、200ng,50μM dNTPs,50mM pH为7.5的Tris-HCl,10mMMgCl2,1mM ATP,10mM Dithiothreitol和80ng待连接的DNA片段。混匀后,37℃条件下孵育1h。
实施例3:检测连接产物
1.PCR方法检测实施例1和2所得的连接产物
3μl反应体系作为模板,10μM引物对T7terminator(5’-TAATACGACTCACTATAGGG-3’)和T7promoter(5’-GCTAGTTATTGCTCAGCGG-3’)各1μl、5μl 2XTaq mixture(Genstar,货号A012),混匀,进行PCR扩增。扩增反应程序94℃,5min;94℃,15s,55℃,15s,72℃,30s,30个循环;72℃,5min。琼脂糖凝胶电泳检测PCR反应产物,结果如图1所示,泳道5、7、8和9中在500bp处出现扩增条带,证明连接成功。
2.产物转化大肠杆菌方法检测连接产物
2μl反应体系中加入protease K,65℃,30min,转化E.coliDH5a。转化程序为冰上孵育30min,42℃热激90s,冰上静置5min,添加500μl LB培养基,37℃振荡培养1.5h;4000rpm/min离心,沉淀菌体全部涂布含氨苄青霉素100μg/ml LB固体培养基;37℃过夜培养后,菌落计数。结果如图2所示,单菌落产生,说明连接反应完成,并且反应体系中相同质量的Ku K19R蛋白(R19折线)比Ku蛋白(K19折线)产生的菌落数(CFU)多。
SEQUENCE LISTING
<110> 佛山科学技术学院
<120> 一种非同源末端体系、制备方法及应用
<130> 2017
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 263
<212> PRT
<213> 人工序列
<400> 1
Met Arg Ser Ile Trp Lys Gly Ser Ile Ala Phe Gly Leu Val Asn Val
1 5 10 15
Pro Val Arg Val Tyr Ser Ala Thr Glu Asp His Asp Ile Lys Phe His
20 25 30
Gln Val His Ala Lys Asp Asn Gly Arg Ile Arg Tyr Lys Arg Val Cys
35 40 45
Glu Val Cys Gly Glu Val Val Glu Tyr Arg Asp Ile Asn Lys Ala Phe
50 55 60
Glu Ser Asp Asp Gly Gln Met Val Val Ile Thr Asp Glu Asp Ile Ala
65 70 75 80
Thr Leu Pro Glu Glu Arg Ser Arg Glu Ile Glu Val Val Glu Phe Ile
85 90 95
Pro Ala Glu Gln Leu Asp Pro Leu Met Tyr Asp Lys Ser Tyr Phe Leu
100 105 110
Glu Pro Asp Ser Lys Ser Ser Lys Ser Tyr Val Leu Leu Ala Lys Thr
115 120 125
Leu Ala Glu Thr Asp Arg Ile Ala Ile Val His Phe Ser Leu Arg Asn
130 135 140
Lys Ser Arg Leu Ala Ala Leu Arg Val Lys Asp Phe Ser Lys Arg Asp
145 150 155 160
Val Met Met Ile His Thr Leu Leu Trp Pro Asp Glu Ile Arg Asp Pro
165 170 175
Asp Phe Pro Ile Leu Asp Lys Glu Val Gln Ile Lys Pro Ala Glu Leu
180 185 190
Lys Met Ala Gly Gln Val Val Glu Ser Met Thr Asp Asp Phe Lys Pro
195 200 205
Asp Leu Tyr His Asp Asp Tyr Gln Glu Gln Leu Arg Glu Leu Val Gln
210 215 220
Ala Lys Leu Glu Gly Gly Glu Ala Phe Ser Val Glu Glu Gln Pro Ala
225 230 235 240
Glu Leu Asp Glu Gly Thr Glu Asp Val Ser Asp Leu Leu Ala Lys Leu
245 250 255
Glu Ala Ser Val Lys Ala Arg
260
<210> 2
<211> 755
<212> PRT
<213> 人工序列
<400> 2
Met Glu Arg Tyr Glu Arg Val Arg Leu Thr Asn Pro Asp Lys Val Leu
1 5 10 15
Tyr Pro Ala Thr Gly Thr Thr Lys Ala Glu Val Phe Asp Tyr Tyr Leu
20 25 30
Ser Ile Ala Gln Val Met Val Pro His Ile Ala Gly Arg Pro Val Thr
35 40 45
Arg Lys Arg Trp Pro Asn Gly Val Ala Glu Glu Ala Phe Phe Glu Lys
50 55 60
Gln Leu Ala Ser Ser Ala Pro Ser Trp Leu Glu Arg Gly Ser Ile Thr
65 70 75 80
His Lys Ser Gly Thr Thr Thr Tyr Pro Ile Ile Asn Thr Arg Glu Gly
85 90 95
Leu Ala Trp Val Ala Gln Gln Ala Ser Leu Glu Val His Val Pro Gln
100 105 110
Trp Arg Phe Glu Asp Gly Asp Gln Gly Pro Ala Thr Arg Ile Val Phe
115 120 125
Asp Leu Asp Pro Gly Glu Gly Val Thr Met Thr Gln Leu Cys Glu Ile
130 135 140
Ala His Glu Val Arg Ala Leu Met Thr Asp Leu Asp Leu Glu Thr Tyr
145 150 155 160
Pro Leu Thr Ser Gly Ser Lys Gly Leu His Leu Tyr Val Pro Leu Ala
165 170 175
Glu Pro Ile Ser Ser Arg Gly Ala Ser Val Leu Ala Arg Arg Val Ala
180 185 190
Gln Gln Leu Glu Gln Ala Met Pro Lys Leu Val Thr Ala Thr Met Thr
195 200 205
Lys Ser Leu Arg Ala Gly Lys Val Phe Leu Asp Trp Ser Gln Asn Asn
210 215 220
Ala Ala Lys Thr Thr Ile Ala Pro Tyr Ser Leu Arg Gly Arg Asp His
225 230 235 240
Pro Thr Val Ala Ala Pro Arg Thr Trp Asp Glu Ile Ala Asp Pro Glu
245 250 255
Leu Arg His Leu Arg Phe Asp Glu Val Leu Asp Arg Leu Asp Glu Tyr
260 265 270
Gly Asp Leu Leu Ala Pro Leu Asp Ala Asp Ala Pro Ile Ala Asp Lys
275 280 285
Leu Thr Thr Tyr Arg Ser Met Arg Asp Ala Ser Lys Thr Pro Glu Pro
290 295 300
Val Pro Lys Glu Ile Pro Lys Thr Gly Asn Asn Asp Lys Phe Val Ile
305 310 315 320
Gln Glu His His Ala Arg Arg Leu His Tyr Asp Leu Arg Leu Glu Arg
325 330 335
Asp Gly Val Leu Val Ser Phe Ala Val Pro Lys Asn Leu Pro Glu Thr
340 345 350
Thr Ala Glu Asn Arg Leu Ala Val His Thr Glu Asp His Pro Ile Glu
355 360 365
Tyr Leu Ala Phe His Gly Ser Ile Pro Lys Gly Glu Tyr Gly Ala Gly
370 375 380
Asp Met Val Ile Trp Asp Ser Gly Ser Tyr Glu Thr Glu Lys Phe Arg
385 390 395 400
Val Pro Glu Glu Leu Asp Asn Pro Asp Asp Ser His Gly Glu Ile Ile
405 410 415
Val Thr Leu His Gly Glu Lys Val Asp Gly Arg Tyr Ala Leu Ile Gln
420 425 430
Thr Lys Gly Lys Asn Trp Leu Ala His Arg Met Lys Asp Gln Lys Asn
435 440 445
Ala Arg Pro Glu Asp Phe Ala Pro Met Leu Ala Thr Glu Gly Ser Val
450 455 460
Ala Lys Tyr Lys Ala Lys Gln Trp Ala Phe Glu Gly Lys Trp Asp Gly
465 470 475 480
Tyr Arg Val Ile Ile Asp Ala Asp His Gly Gln Leu Gln Ile Arg Ser
485 490 495
Arg Thr Gly Arg Glu Val Thr Gly Glu Tyr Pro Gln Phe Lys Ala Leu
500 505 510
Ala Ala Asp Leu Ala Glu His His Val Val Leu Asp Gly Glu Ala Val
515 520 525
Ala Leu Asp Glu Ser Gly Val Pro Ser Phe Gly Gln Met Gln Asn Arg
530 535 540
Ala Arg Ser Thr Arg Val Glu Phe Trp Ala Phe Asp Ile Leu Trp Leu
545 550 555 560
Asp Gly Arg Ser Leu Leu Arg Ala Lys Tyr Ser Asp Arg Arg Lys Ile
565 570 575
Leu Glu Ala Leu Ala Asp Gly Gly Gly Leu Ile Val Pro Asp Gln Leu
580 585 590
Pro Gly Asp Gly Pro Glu Ala Met Glu His Val Arg Lys Lys Arg Phe
595 600 605
Glu Gly Val Val Ala Lys Lys Trp Asp Ser Thr Tyr Gln Pro Gly Arg
610 615 620
Arg Ser Ser Ser Trp Ile Lys Asp Lys Ile Trp Asn Thr Gln Glu Val
625 630 635 640
Val Ile Gly Gly Trp Arg Gln Gly Glu Gly Gly Arg Ser Ser Gly Ile
645 650 655
Gly Ala Leu Val Leu Gly Ile Pro Gly Pro Glu Gly Leu Gln Phe Val
660 665 670
Gly Arg Val Gly Thr Gly Phe Thr Glu Lys Glu Leu Ser Lys Leu Lys
675 680 685
Asp Met Leu Lys Pro Leu His Thr Asp Glu Ser Pro Phe Asn Ala Pro
690 695 700
Leu Pro Lys Val Asp Ala Arg Gly Val Thr Phe Val Arg Pro Glu Leu
705 710 715 720
Val Gly Glu Val Arg Tyr Ser Glu Arg Thr Ser Asp Gly Arg Leu Arg
725 730 735
Gln Pro Ser Trp Arg Gly Leu Arg Pro Asp Lys Thr Pro Asp Glu Val
740 745 750
Val Trp Glu
755
<210> 3
<211> 20
<212> DNA
<213> 人工序列
<400> 3
tgtagacgcg gaccggcacg 20
<210> 4
<211> 20
<212> DNA
<213> 人工序列
<400> 4
cgtgccggtc cgcgtctaca 20

Claims (3)

1.一种非同源末端体系,其特征在于,包括Ku K19R蛋白和LigD蛋白,所述Ku K19R蛋白是如序列表中的SEQ ID№.1所示的氨基酸序列组成的蛋白质,所述LigD蛋白是如序列表中的SEQ ID№.2所示的氨基酸序列组成的蛋白质。
2.权利要求1所述的非同源末端体系在连接双链DNA片段的应用。
3.根据权利要求2所述的非同源末端体系在连接双链DNA片段的应用,包括步骤:将待连接的双链DNA片段与非同源末端体系混合,在37℃条件下孵育1小时。
CN201710414508.XA 2017-06-05 2017-06-05 一种非同源末端体系、制备方法及应用 Expired - Fee Related CN107298698B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710414508.XA CN107298698B (zh) 2017-06-05 2017-06-05 一种非同源末端体系、制备方法及应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710414508.XA CN107298698B (zh) 2017-06-05 2017-06-05 一种非同源末端体系、制备方法及应用

Publications (2)

Publication Number Publication Date
CN107298698A CN107298698A (zh) 2017-10-27
CN107298698B true CN107298698B (zh) 2020-12-01

Family

ID=60134667

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710414508.XA Expired - Fee Related CN107298698B (zh) 2017-06-05 2017-06-05 一种非同源末端体系、制备方法及应用

Country Status (1)

Country Link
CN (1) CN107298698B (zh)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104673816A (zh) * 2015-03-05 2015-06-03 广东医学院 一种pCr-NHEJ载体及其构建方法及其用于细菌基因定点敲除的应用

Also Published As

Publication number Publication date
CN107298698A (zh) 2017-10-27

Similar Documents

Publication Publication Date Title
WO2022227880A1 (zh) 一种新型磷酸化腺苷酰化酶及其制备方法与应用
JP6963238B2 (ja) Dnaポリメラーゼ変異体
CN113136374B (zh) 一种重组突变型Tn5转座酶的制备及应用
EP3613851A1 (en) Recombinant dna polymerase
CN113980141B (zh) 基于大肠杆菌素e家族dna酶的蛋白质复合物及其在人工蛋白支架中的应用
US20220090090A1 (en) A method for assembling circular and linear dna molecules in an ordered manner
JP2007043963A (ja) Dnaリガーゼ変異体
CN113166270A (zh) 融合蛋白及其应用
CN107298698B (zh) 一种非同源末端体系、制备方法及应用
CN104946705B (zh) 一种连续化生产c-di-AMP的方法
CN114645033B (zh) 一种三磷酸核苷水解酶及其纯化方法和应用
CN106701629B (zh) 荧光假单胞菌、荧光假单胞菌脂肪酶lipasebj10及其应用
CN113774039B (zh) 重组型dna聚合酶及其应用
CN114875002B (zh) 一种精氨酸突变的dna/rna连接酶
JP2008245604A (ja) 高効率耐熱性dnaリガーゼ
CN107974442A (zh) 内切葡聚糖酶、其编码基因cel5A-h42及其应用
KR102152142B1 (ko) Cas10/Csm4를 이용한 사이클릭 올리고아데닐레이트 제조방법
CN107828762B (zh) 内切葡聚糖酶、其编码基因cel5A-h50及其应用
CN113564141B (zh) 单细胞基因组扩增酶突变体及其应用
KR102200330B1 (ko) Cas10/Csm4 서브 복합체를 이용한 사이클릭 뉴클레오타이드 제조방법
CN113151213B (zh) 一种高忠实性dna聚合酶及其制备方法和pcr应用
CN109735524B (zh) 一种具有嗜冷特性的碱性果胶酶及其应用
CN106191018B (zh) 一种来源于虎眼万年青的尿苷-5’-二磷酸木糖合成酶,其核苷酸序列及应用
JP2009148205A (ja) 高反応性耐熱性dnaリガーゼ
CN106191019B (zh) 一种截短型尿苷-5’-二磷酸木糖合成酶,其核苷酸序列及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201201

CF01 Termination of patent right due to non-payment of annual fee